ARPC5 and colorectal carcinoma: In contrast, positive immunostaining for CORO1C, RAD23B, and ARPC5 was observed in 55.7% (535/961), 84.0% (420/500), and 85.8% (429/500) of the CRC tumor tissues, respectively, showing significant upregulation compared with the adjacent noncancerous tissues (all P < 0.0001).